Abstract
Five compounds -1, 2, 3, 4, and 5 were placed into tissue culture similarly to isoniazid at concentrations ranging from 0.03125 mg/mL to 2.00 mg/mL, with Mycobacterium tuberculosis. Compounds 1 and 5 showed substantial growth inhibition at the lowest concentration of 0.03125 mg/mL, whereas compounds 2, 3, and 4 demonstrated similar effects starting at 0.0625 mg/mL. Compounds 2 and 3 showed polar surface area of 55.12 A2, suitable for penetrating the blood-brain barrier. Hierarchical cluster analysis, principal coordinates analysis, and principal components analysis were utilized to analyze numerical values of properties for all drugs and showed that isoniazid is highly similar to compounds 2 and 3, with compound 1 distinct from all other drugs, with compounds 4 and 5 having high similarity. This comparison was confirmed by by principal coordinates analysis and principal components analysis. Multiple regression analysis produced an equation that accurately predicts formula weight for similar drugs utilizing molar refractivity, molar volume, parachor, and polar surface area. Compounds 1, 2, 3, and isoniazid showed no violations of the Rule of 5, which indicates properties that enhance drug absorbance. Compounds 2, 3, 4, and 5 were synthesized by utilizing microwave methodology.
Keywords: Tuberculosis, Mycobacteria, Hydrazine, Isoniazid, Antibacterial, MDR
Letters in Drug Design & Discovery
Title: Design and In Vitro Evaluation of Five Inhibitors of Mycobacterium Tuberculosis
Volume: 4 Issue: 2
Author(s): Ronald Bartzatt, Suat L. G. Cirillo and Jeffrey D. Cirillo
Affiliation:
Keywords: Tuberculosis, Mycobacteria, Hydrazine, Isoniazid, Antibacterial, MDR
Abstract: Five compounds -1, 2, 3, 4, and 5 were placed into tissue culture similarly to isoniazid at concentrations ranging from 0.03125 mg/mL to 2.00 mg/mL, with Mycobacterium tuberculosis. Compounds 1 and 5 showed substantial growth inhibition at the lowest concentration of 0.03125 mg/mL, whereas compounds 2, 3, and 4 demonstrated similar effects starting at 0.0625 mg/mL. Compounds 2 and 3 showed polar surface area of 55.12 A2, suitable for penetrating the blood-brain barrier. Hierarchical cluster analysis, principal coordinates analysis, and principal components analysis were utilized to analyze numerical values of properties for all drugs and showed that isoniazid is highly similar to compounds 2 and 3, with compound 1 distinct from all other drugs, with compounds 4 and 5 having high similarity. This comparison was confirmed by by principal coordinates analysis and principal components analysis. Multiple regression analysis produced an equation that accurately predicts formula weight for similar drugs utilizing molar refractivity, molar volume, parachor, and polar surface area. Compounds 1, 2, 3, and isoniazid showed no violations of the Rule of 5, which indicates properties that enhance drug absorbance. Compounds 2, 3, 4, and 5 were synthesized by utilizing microwave methodology.
Export Options
About this article
Cite this article as:
Bartzatt Ronald, G. Cirillo L. Suat and Cirillo D. Jeffrey, Design and In Vitro Evaluation of Five Inhibitors of Mycobacterium Tuberculosis, Letters in Drug Design & Discovery 2007; 4 (2) . https://dx.doi.org/10.2174/157018007779422451
DOI https://dx.doi.org/10.2174/157018007779422451 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Developments in Particulate-Based Vaccines
Recent Patents on Drug Delivery & Formulation Design, Synthesis and Antitubercular Evaluation of New Benzimidazole Scaffolds
Anti-Infective Agents Nanotechnology-Based Approaches for Combating Tuberculosis: A Review
Current Nanomaterials Improving DNA Vaccine Performance Through Vector Design
Current Gene Therapy Potential Therapeutic Relevance of CRISPR/Cas9 Guided Epigenetic Regulations for Neuropsychiatric Disorders
Current Topics in Medicinal Chemistry QSAR and Docking Studies of N-hydroxy Urea Derivatives as Flap Endonuclease-1 Inhibitors
Current Computer-Aided Drug Design Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4
Current Drug Metabolism Mesenchymal Stem Cells: A New Generation of Therapeutic Agents as Vehicles in Gene Therapy
Current Gene Therapy Current Bioactive Azole-Containing Natural Products
Current Bioactive Compounds Evaluation of Small Molecule Tuberculostats for Targeting Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Intelligently Applying Artificial Intelligence in Chemoinformatics
Current Topics in Medicinal Chemistry Design, Synthesis and Evaluation of Antimicrobial Activity of Novel Oxazine Derivatives using Betti’s Protocol
Letters in Drug Design & Discovery Recent Advances in the Synthesis of Biologically Active Cinnoline, Phthalazine and Quinoxaline Derivatives
Current Organic Chemistry The Asymmetric Pictet – Spengler Reaction
Current Organic Synthesis Glycoconjugates of Quinolines: Application in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Effects of Mefepronic Acid (2-Phenoxy-2-Methyl Propionic Acid) on Hepatic Metabolism and Reproductive Parameters in Postpartum Dairy Cows
Endocrine, Metabolic & Immune Disorders - Drug Targets Progress on the Discovery of Inhibitors of InhA, the FAS II Enoyl-ACP Reductase TB Drug Discovery Targeted on InhA
Letters in Drug Design & Discovery Microbiome in Chronic Obstructive Pulmonary Disease: Role of Natural Products Against Microbial Pathogens
Current Medicinal Chemistry Solubilization and Antitumor Activity of Oleanolic Acid Lysinate
Current Analytical Chemistry Recent Advances in the Synthesis of New Antimycobacterial Agents Based on the 1H-1,2,3-Triazoles
Current Topics in Medicinal Chemistry